REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
REGENERON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$782.04−8.70 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $82.90B
- P/E (TTM)
- 19.3
- Dividend yield
- –
Share price
+$203.99 (+35.29%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
REGENERON PHARMACEUTICALS, INC. grew revenue 9.3% to $15.53B over the twelve months to Jun 30, 2026. Operating income rose 0.1% to $3.84B, moving the operating margin from 27.0% to 24.7%. Free cash flow was $3.76B, down 2.4% from a year earlier.
Revenue
$15.53B
+9.3% vs. a year earlier
Operating income
$3.84B
+0.1% vs. a year earlier
Free cash flow
$3.76B
-2.4% vs. a year earlier
EPS, diluted
$40.44
+1.9% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $82.90B
- P/E ratio
- 19.3
- Price to sales
- 5.34
- Price to book
- 2.61
- Dividend yield
- –
- Free cash flow yield
- 4.54%
Fundamentals
- Revenue
- $15.53B
- Net income
- $4.33B
- EPS, diluted
- $40.44
- Free cash flow
- $3.76B
- Book value per share
- $299.16
- Diluted shares
- 106M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$15.53B+9.3% YoY
Gross profit
–
Operating income
$3.84B+0.1% YoY
Net income
$4.33B-2.9% YoY
EPS, diluted
$40.44+1.9% YoY
Free cash flow
$3.76B-2.4% YoY
Reported periodTrailing twelve months